|
|
Michael Johnston: Despite some rather significant bumps along the road in 2011, many asset classes are now well into positive territory on a one year trailing basis as January draws to a close, riding high thanks to a strong finish to last year and start to 2012. Included on that list are a number of Read more…
IBB, LBND, NASDAQ:BIB, TYD, UGL
In trading on Monday, the iShares Nasdaq Biotechnology (NASDAQ:IBB) is outperforming other ETFs, up about 4.78% on the day. Also up on the day are the Read more…
Eric Dutram: The past week was, again, extremely choppy as European rumors took center stage, leaving investors fixated on events coming out of Germany and France. While some progress was definitely made in the negotiations, this week’s summit could play a key role in determining the long term Read more…
Ron Rowland: Like many of you, I’m a Baby Boomer. Now I find myself north of 50 and the prospect of getting “old” isn’t very attractive. What does this have to do with investing and ETFs? Plenty! Read more…
IBB, NASDAQ:BIB, NASDAQ:BIS, NYSE:FBT, PBE, XBI
Stocks were obliterated on Wednesday as volume surged. The markets sold off sharply at the open, rallied modestly at the 11:00 am reversal period and spent the remainder of the day in a downward spiral. All five major indices opened at the high and closed near the dead lows of the day. Read more…
Stocks rallied sharply on Tuesday and closed near session highs. All of the major indices added more than 1.5%. The Nasdaq (NASDAQ:QQQ) put in an impressive performance led largely by the recent good fortune of Apple Inc. (NASDAQ:AAPL) and Google (NASDAQ:GOOG). The tech rich index led Read more…
David Fry: Our goal in this profile is to help investors wade through the many competing ETF offerings available. Using our long experience as an ETF publication, and nearly 40 years in the investment business, we can help select those ETFs that matter and may or may not be repetitive. Read more…
Alex Strashny: Recommended funds. Our main recommendation this week is real estate (NYSE:IYR). Its expected return jumped last week as it gained +4.46% in 5 days on slightly higher volume. However, its risk is high and has increased slightly. Because of the high risk in IYR, some Read more…
Alex Strashny: Recommended funds: Biotech (NYSE:IBB) remains our primary recommendation this week. With the +1.68% rise and slightly higher volume over the past week, the expected return is definitely positive and slightly higher. IBB’s risk has decreased over the past week Read more…
Stocks rallied sharply yesterday but on lighter volume. After nine days of continuous selling the major indices finally saw a day of strong gains. High beta stocks led the advance as the small-cap Russell 2000 (NYSE:IWM), S&P MidCap 400 and the Nasdaq (NASDAQ:QQQ) tacked on gains of Read more…
Alex Strashny: While we still like the strong uptrend in energy (NYSE:XLE), its risk has increased so much that we are reducing our position in it. Though the uptrend goes back to the Fall of 2010, Read more…
Equities advanced for the second straight day but on lower trade. Unlike Wednesday however, stocks held their ground to finish near session highs. For the second time in as many days the Read more…
Red flags are flying everywhere as we travel farther into the “sell in May and go away” period of the year.” At Wall Street Sector Selector, we remain in a defensive posture and continue to enjoy Read more…
I’m a momentum investor. What does that mean? I just try to identify leading market sectors and then keep my portfolio aligned with them. Sometimes the strength is fairly obvious, and at other Read more…
IBB, IHF, NASDAQ:BIB, NYSE:PPH, PTH
Most Comments